UbiquiTx, a spin-out from Cornell University and MIT, is focused on leveraging machine learning and protein engineering to develop programmable protein-modulating therapies. The company’s computational platform allows the designing of motif, mutant and PTM-specific peptides to pathogenic proteins from sequence alone based on known interactions found in nature.
